ClinicalTrials.Veeva

Menu
S

StracSkin, PLLC. | Portsmouth, NH

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

LY4005130
Risankizumab
LY2439821
Ustekinumab
Deucravacitinib
Tirzepatide
Ritlecitinib
Lutikizumab
Ixekizumab
JNJ-77242113

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 9 total trials

A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.

The purpose of this study is to learn about the safety and effects of the study medicine (called Ritlecitinib) for the possible treatment of hidraden...

Enrolling
Hidradenitis Suppurativa
Drug: Ritlecitinib
Drug: Placebo

The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deu...

Active, not recruiting
Plaque Psoriasis
Drug: Deucravacitinib Matching Placebo
Drug: JNJ-77242113 Matching Placebo

The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo...

Enrolling
Vitiligo
Non-Segmental Vitiligo (NSV)
Drug: Placebo
Drug: LY4005130

The purpose of this study is to evaluate how well LY4005130 works in participants with severe alopecia areata (hair loss) when compared with placebo,...

Enrolling
Alopecia Areata
Drug: LY4005130
Drug: Placebo

Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in ar...

Enrolling
Hidradenitis Suppurativa
Drug: Placebo
Drug: Lutikizumab

The purpose of this study is to assess the effectiveness and safety of a single dose of IPN10200 compared to placebo (double-blind phase) and how wel...

Enrolling
Moderate to Severe Glabellar Lines
Biological: IPN10200
Biological: Placebo

The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participan...

Enrolling
Psoriasis
Overweight or Obesity
Drug: Tirzepatide

A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis

Enrolling
Plaque Psoriasis
Drug: Ustekinumab
Drug: Deucravacitinib

Trial sponsors

Lilly logo
AbbVie logo
Bristol-Myers Squibb (BMS) logo
Ipsen logo
Janssen (J&J Innovative Medicine) logo
Pfizer logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems